You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

NORMOZIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Normozide, and when can generic versions of Normozide launch?

Normozide is a drug marketed by Schering and is included in one NDA.

The generic ingredient in NORMOZIDE is hydrochlorothiazide; labetalol hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; labetalol hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NORMOZIDE?
  • What are the global sales for NORMOZIDE?
  • What is Average Wholesale Price for NORMOZIDE?
Summary for NORMOZIDE
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 72
DailyMed Link:NORMOZIDE at DailyMed
Drug patent expirations by year for NORMOZIDE

US Patents and Regulatory Information for NORMOZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-001 Apr 6, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-004 Apr 6, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-002 Apr 6, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NORMOZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-001 Apr 6, 1987 ⤷  Sign Up ⤷  Sign Up
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-002 Apr 6, 1987 ⤷  Sign Up ⤷  Sign Up
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-003 Apr 6, 1987 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for NORMOZIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0503785 CA 2011 00026 Denmark ⤷  Sign Up PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0454511 99C0009 Belgium ⤷  Sign Up PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0502314 SPC/GB02/037 United Kingdom ⤷  Sign Up PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.